Ibáñez Sanz, GemmaDíez Villanueva, AnnaVilorio Marqués, LauraGracia, EstherAragonés, NuriaOlmedo Requena, RocíoLlorca, JavierVidán, JuanaAmiano, PilarNos, PilarFernández Tardón, GuillermoRada, RicardoChirlaque, María DoloresGuinó, ElisabetDávila Batista, VerónicaCastaño Vinyals, GemmaPérez Gómez, BeatrizMirón Pozo, BenitoDierssen Sotos, TrinidadEtxeberria Andueza, JaioneMolinuevo, AmaiaÁlvarez Cuenllas, BegoñaKogevinas, ManolisPollán, MarinaMoreno, Víctor2018-09-192018-09-1920182045-2322 (Electronic)10.1038/s41598-018-20349-6https://academica-e.unavarra.es/handle/2454/30721A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47–1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62–0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.8 p.application/pdfeng© The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Colorectal cancerGlucosamineChondroitin sulphateinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessAcceso abierto / Sarbide irekia